79 results
8-K
EX-99.1
GYRE
Gyre Therapeutics Inc
14 Feb 24
Results of Operations and Financial Condition
5:16pm
of the situation in the Middle East, increased, creating an unpredictable environment.
The Japanese economy has also demonstrated a certain level
8-K/A
EX-99.1
GYRE
Gyre Therapeutics Inc
12 Jan 24
Completion of Acquisition or Disposition of Assets
4:01pm
to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments
424B3
ow2hf5 hkkw4d96a
1 Nov 23
Prospectus supplement
5:18pm
8-K
EX-14.1
hedkxf8l 8gv4s1eo2dt
30 Oct 23
Entry into a Material Definitive Agreement
5:17pm
8-K
h5jl80dt14uadz6y4rh
30 Oct 23
Entry into a Material Definitive Agreement
5:17pm
424B3
0jaqa
27 Oct 23
Prospectus supplement
5:10pm
S-3/A
i5m1d6x45dvlx4ps0 ru
13 Oct 23
Shelf registration (amended)
4:25pm
DEFM14A
0bf xya2tdt3ni
20 Jul 23
Proxy related to merger
8:57am
PRER14A
qqq 7oarkbgtnhe4v
15 May 23
Preliminary revised proxy
4:02pm
PREM14A
al3rbiudzh
30 Mar 23
Preliminary proxy related to merger
4:48pm
425
EX-2.1
uqcmfj2vpls
27 Dec 22
Business combination disclosure
7:02am
425
EX-2.2
xufu5wbtzk im
27 Dec 22
Business combination disclosure
7:02am
8-K
EX-2.1
4zyf 9l4v8bvobhq4xt
27 Dec 22
Catalyst Biosciences Completes First Steps in Reverse Merger Plan
7:00am